XM tidak memberikan layanan kepada penduduk Amerika Serikat.
G
G

GSK


Berita

A second Zantac cancer trial ends with hung jury

A second Zantac cancer trial ends with hung jury Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man
G
P
S

GSK settles two California lawsuits related to heartburn drug Zantac

UPDATE 1-GSK settles two California lawsuits related to heartburn drug Zantac Adds background and context Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in either settlement, it said in a statement.
G
P
S

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

UPDATE 1-GSK's RSV, Shingles vaccines show on-par immune response in joint trial Adds details on study in paragraph 2, company's statement in paragraph 4 Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
G

GSK's RSV vaccine meets main goal when co-administered with shingles shot

GSK's RSV vaccine meets main goal when co-administered with shingles shot Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age. The company said co-administration of the vaccines generated an immune response that was at least on-par with separate administration.
G

Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma

BRIEF-Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma Sept 17 (Reuters) - GSK plc GSK.L : GSK PLC - JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA Source text for Eikon: ID:nRSQ4071Ea Further company coverage: GSK.L
G

Iteos falls after mid-stage study results for lung cancer drug

BUZZ-Iteos falls after mid-stage study results for lung cancer drug Updates ** Shares of cancer drug developer Iteos Therapeutics ITOS.O slide 23.6% to $12.76 ** Stock had risen 27 .3% t o $21.26 in premarket trade ** Co says its lung cancer drug belrestotug, in combination with GSK's GSK.L drug dostarlimab, showed higher percentage of reduction or
G

Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone

BUZZ-Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone ** Shares of cancer drug developer Iteos Therapeutics ITOS.O rise 14.7% at $19.16 premarket ** Co says its lung cancer drug, belrestotug, in combination with GSK's GSK.L drug, dostarlimab, showed reduction or disappearance of tumor in 63.3%-76.7% patients, vs
G

Zenas BioPharma shares rise nearly 8% in market debut

UPDATE 2-Zenas BioPharma shares rise nearly 8% in market debut Adds details on U.S. IPO market in paragraph 4-5, details on the company from paragraph 6 onwards Sept 13 (Reuters) - Shares of Bristol-Myers Squibb-backed Zenas BioPharma ZBIO.O rose nearly 8% in their Nasdaq debut on Friday, a sign of recovery for the U.S. initial public offering market in 2024 after two subpar years.
C
G

GSK's Blenrep Receives Breakthrough Therapy Designation In China

BRIEF-GSK's Blenrep Receives Breakthrough Therapy Designation In China Sept 13 (Reuters) - GSK plc GSK.L : GSK PLC - CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP GSK PLC - BLENREP RECEIVES BREAKTHROUGH THERAPY DESIGNATION IN CHINA Source text for Eikon: ID:nRSM0429Ea Further company coverage: GSK.L
G

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial By Kashish Tandon Sept 12 (Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for infections caused by drug resistant "superbugs" or microbes.
G
P

UK Stocks-Factors to watch on Sept 12

UPDATE 1-UK Stocks-Factors to watch on Sept 12 Adds news items, updates futures Sept 12 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Thursday, with futures FFIc1 up 1.2%. * GSK: British drugmaker GSK GSK.L announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
G
S
D
R

British drugmaker GSK moves mRNA flu vaccine to late-stage trials

UPDATE 1-British drugmaker GSK moves mRNA flu vaccine to late-stage trials Adds details and background throughout Sept 12 (Reuters) - British drugmaker GSK GSK.L announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development.
G

GSK's mRNA flu vaccine programme to proceed to late-stage trials

GSK's mRNA flu vaccine programme to proceed to late-stage trials Sept 12 (Reuters) - British drugmaker GSK GSK.L on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development. Data showed a vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults, GSK said.
G

GSK Announces Positive MRNA Flu Vaccine Phase II Headline Data

BRIEF-GSK Announces Positive MRNA Flu Vaccine Phase II Headline Data Sept 12 (Reuters) - GSK plc GSK.L : POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA VACCINE CANDIDATE SHOWS POSITIVE IMMUNE RESPONSES IN YOUNGER AND OLDER ADULTS DATA SUPPORT PROGRESSION TO PHASE III CLINICAL TRIALS MRNA INFLUENZA VACCINE PROGRAMME TO PROGRESS TO LATE-STAGE DEVEL
G

UK Stocks-Factors to watch on Sept 11

UPDATE 1-UK Stocks-Factors to watch on Sept 11 Adds news items, updates futures Sept 11 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures up 0.15%. * RIGHTMOVE: Britain's largest real estate portal Rightmove RMV.L rejected the 5.6 billion pound ($7.32 billion) cash-and-stock takeover proposal from Australia's REA Group REA.AX , it said, citing that the bid undervalued its prospects.
B
G
N
R
R
A

GSK's experimental herpes vaccine fails to meet main goal in trial

UPDATE 1-GSK's experimental herpes vaccine fails to meet main goal in trial Adds details on the virus and GSK's next moves from paragraph 2 Sept 11 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
G

GSK Says GSK3943104 HSV Vaccine Candidate Fails To Meet Primary Efficacy Objective

BRIEF-GSK Says GSK3943104 HSV Vaccine Candidate Fails To Meet Primary Efficacy Objective Sept 11 (Reuters) - GSK plc GSK.L : GSK PLC - UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL GSK PLC - COMPLETES PRIMARY DATA ANALYSIS OF PHASE II HSV VACCINE TRIAL GSK PLC - GSK3943104 HSV VACCINE CANDIDATE FAILS TO MEET PRIMARY EFFICACY OBJECTIVE GSK PLC
G

GSK's experimental HSV vaccine fails to meet main goal in trial

GSK's experimental HSV vaccine fails to meet main goal in trial Sept 11 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial. Reporting by Yadarisa Shabong in Bengaluru; Editing by
G

Big Pharma lacks motive to prep for new pandemics

BREAKINGVIEWS-Big Pharma lacks motive to prep for new pandemics The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 10 (Reuters Breakingviews) - Covid-19 underlined the critical importance of vaccines. The pandemic caused 16 million global deaths, and the current scare surrounding Mpox emphasises how citizens remain fearful of fresh outbreaks.
A
G
P
S

Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO

Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO Sept 6 (Reuters) - Zenas BioPharma, which is developing immunology-based therapies, said on Friday it is targeting a valuation of as much as $689.7 million in its initial public offering in the United States. The company, backed by drugmaker Bristol-Myers Squibb BMY.N , is looking to raise as much as $211.7 million by offering 11.76 million shares priced between $16 and $18 each.
C
G



Kondisi

Aset Populer

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.